Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04419389
Title APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
Recruitment Suspended
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Aprea Therapeutics

mantle cell lymphoma

chronic lymphocytic leukemia


Acalabrutinib + APR-246

APR-246 + Rituximab + Venetoclax

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST